GGrantIndex
← Search

ACTG 265: A PHASE I/II STUDY OF SAFETY &IMMUNOGENICITY OF LIVE-ATTENUATED

$6,450M01FY2004RRNIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

View original record on NIH RePORTER →